Denosumab
- Generic Name
- Denosumab
- Brand Names
- Prolia, Xgeva, Wyost, Jubbonti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 615258-40-7
- Unique Ingredient Identifier
- 4EQZ6YO2HI
- Background
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and...
- Indication
Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be use...
- Associated Conditions
- Bone Fractures, Bone Giant Cell Tumor, Bone Loss, Bone pain, Spinal Cord Compression, Bone destruction, High risk of fracture Osteoporosis, Refractory Hypercalcemia of malignancy
- Associated Therapies
- -
Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Stanley Dudrick's Memorial Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT02853539
- Locations
- 🇵🇱
Stanley Dudrick's Memorial Hospital, Skawina, Poland
Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 4
- Registration Number
- NCT02792413
- Locations
- 🇫🇷
CHU Lyon Sud, Nephrology department, Lyon, France
🇫🇷AIDER, Montpellier, France
🇫🇷Clinique Médipole Cabestany, Cabestany, France
RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints
- Conditions
- Interventions
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 100
- Registration Number
- NCT02771860
- Locations
- 🇧🇪
UZ Ghent, Gent, Belgium
The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2017-08-11
- Target Recruit Count
- 60
- Registration Number
- NCT02760979
Preventing Osteoporosis Using Denosumab
- Conditions
- Interventions
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Susan L. Greenspan
- Target Recruit Count
- 201
- Registration Number
- NCT02753283
- Locations
- 🇺🇸
UPMC Senior Communities, Pittsburgh, Pennsylvania, United States
4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
- Conditions
- Interventions
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 263
- Registration Number
- NCT02721433
- Locations
- 🇨🇦
The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Denosumab as an add-on Neoadjuvant Treatment (GeparX)
- Conditions
- Interventions
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 780
- Registration Number
- NCT02682693
- Locations
- 🇩🇪
Charité Campus Mitte, Berlin, Germany
Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in Children
- Conditions
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- St. Justine's Hospital
- Registration Number
- NCT02677246
- Locations
- 🇨🇦
St. Justine 's Hospital, Montreal, Quebec, Canada
Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Children's Hospital of Eastern Ontario
- Target Recruit Count
- 10
- Registration Number
- NCT02632916
- Locations
- 🇨🇦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Denosumab and MRI Breast Imaging
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Alison Stopeck
- Target Recruit Count
- 42
- Registration Number
- NCT02613416
- Locations
- 🇺🇸
Stony Brook University Cancer Center, Stony Brook, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.